Discovery in the Academy

Premium

When it comes to high-throughput screening, you probably think of research at a large pharmaceutical company. Pharmas spend countless hours and untold sums of money searching for drugs and drug targets, refining the process, and searching some more. At the same time, academia tends to ignore the further-downstream possibilities of high-throughput screening, focusing on more basic biological interests. But not the University of Kansas. The school is carving out a place for itself on the academic side of drug discovery, particularly to fill unmet clinical needs such as rare cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.